Hantaan virus (HTNV), a member of the family Bunyaviridae, is a major agent causing haemorrhagic fever with renal syndrome, a high-mortality-rate disease threatening approximately 150 000 people around the world yearly. The 3D8 mAb displays a neutralizing activity to HTNV infection. In this study, the B-cell epitopes of HTNV glycoproteins (GPs) were finely mapped by peptide scanning. A new B-cell epitope 882 GFLCPEFPGSFRKKC 896 of HTNV, which locates on Gc, has been screened out from a set of 15-mer synthesized peptides covering the full-length of HTNV-GPs. It has been shown by the alanine-scanning technique that 885 C, 893 R, 
Hantaan virus (HTNV), a member of the genus Hantavirus residing in the family Bunyaviridae, is the major agent causing haemorrhagic fever with renal syndrome (HFRS). In past decades, 12 000-20 000 HFRS cases have been registered with the China Center for Disease Control, with a mortality rate as high as 12 % (Jonsson et al., 2010) .
The HTNV genome comprises trisegmented negativesense, ssRNAs. The three segments, S (small), M (medium) and L (large), encode the nucleocapsid protein (NP), envelope glycoproteins (Gn and Gc) and viral RNA-dependent RNA polymerase (RdRp), respectively. It is well established that the NP is the major immunogen for humoral immune response, and it induces antibody production within several days after a hantavirus infection. Thus, the HTNV-NP has also been used as a diagnostic agent. Surface-expressed HTNV-GPs play important roles in virus attachment and entry at the initial stages of the virus infection. It has been demonstrated that GPs contain virus-neutralizing epitopes (Arikawa et al., 1989 (Arikawa et al., , 1992 . The epitopes on both the NP (Lundkvist et al., 1995; Yoshimatsu et al., 1996) and the GPs (de Carvalho Nicacio et al., 2000; Liang et al., 2003) of Old World hantaviruses and some New World hantaviruses (Tischler et al., 2005) have been extensively investigated. Xu et al. (2002) prepared the 3G1 and 3D8 neutralizing mAbs against HTNV infection. The 3G1 and 3D8 mAbs showed a potent virus neutralizing activity both in vitro and in vivo. They protected susceptible suckling mice from HTNV infection, even when the mAbs were administrated 1 day before and/or 7 days after a virus challenge (Xu et al., 2002) . However, little research has been done on the binding sites of 3G1 and 3D8 mAbs. So far only one epitope 96 
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105 recognized by 3G1 mAb has been identified by the phage-displayed peptide library (Lü et al., 2009) . The binding sites of 3D8 mAb remain unclear.
In the present study, the epitopes of GPs recognized by the 3D8 mAb were mapped by using the Pepscan methods and the specificities of the binding with the 3D8 mAb were further confirmed by competitive ELISA (cELISA). Then the crucial amino acid residues of the epitope were identified by the alanine-scanning method. Identification of neutralizing epitopes may provide new insight into the protective mechanism of the neutralizing mAb and have implications for hantavirus vaccinology.
Firstly, we mapped the neutralizing epitope of HTNV-GPs by an indirect ELISA (iELISA) combined with the dot-blot technique. One set of 281 pentadecapeptides, representing the entire sequence of HTNV-GPs (UniProtKB/Swiss-Prot ID: P08668-1) was obtained from the Lian Mei Technology Co. Ltd. Each peptide was continuously shifted by four residues from one peptide to the next. In the first round of screening, we grouped these peptides as follows: group 1, from no. 1 to 10; group 2, from no. 11 to 20......; group 27, from no. 261 to 270; and group 28, from no. 271 to 281. For iELISA, mixed peptides of each group and irrelative peptides (negative control) were coated on a 96-well microtitre plate at 10 mM per 100 ml per well and reacted with 2 mg 3D8 mAb ml
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. Then, the reaction of haptens and antibody was detected by HRP-conjugated goat antimouse IgG (Pierce) and TMB (eBioscience) solution, followed by the enzymic reaction, which was stopped with 2 M H 2 SO 4 , and the values were measured by scanning OD 450 using a microplate reader (Bio-Rad). Differences were examined by one-way ANOVA, and the differences were considered significant at P,0.05. For dot blot, 1 mM of each peptide was dot blotted to the nitrocellulose membrane and reacted with 1 mg 3D8 mAb ml
. The binding of immune complexes was measured by HRPconjugated goat anti-mouse IgG (Pierce), and subsequent detection was performed using the ECL system (Alpha Innotech). Both iELISA (Fig. 1a) and dot blot (Fig. 1b) have indicated that group 23 had the highest antibody binding with the 3D8 mAb. Although group 5 also showed activity to the 3D8 mAb in iELISA (Fig. 1a) , it failed in the dot blot (Fig. 1b) (Fig. 1c) .
Then, the specificity of the bindings between peptides and the 3D8 mAb were further assessed. The procedure of cELISA was similar to iELISA. The peptides that had positive results by using the Pepscan method were coated on 96-well microtitre plates. The 3D8 mAb was mixed with the competitor peptides that were diluted in a series of concentrations. Then, the mixture was added to react with the coating peptides. The immune complexes were detected and valued as the iELISA described before. Blocking efficiency was quantitatively assessed by comparing the OD values. The OD values obtained without any competitor were set at a 0 % inhibition rate (maximal binding). The OD values obtained by the 3D8 mAb applied to the control wells without the coating antigen were set at a 100 % inhibition rate (background level). The line graph has illustrated that, compared with other peptides, only the no. 221 peptide 881 KGFLCPEFPGSFRKK 895 has the ability to inhibit the reaction between the 3D8 mAb and the coating peptide no. 221 in a dose-dependent manner (Fig. 1d) . When the concentration of the competitor peptide no. 221 climbed to 20 mM, the inhibition rate reached 78.7 %. Thus, it has been demonstrated that the no. 221 peptide 881 KGFLCPEFPG-SFRKK 895 binds specifically to the 3D8 mAb.
To further identify the precise binding site of the 3D8 mAb, another serial of 15-mer peptides which ranged from 878 to 898 aa and overlapped by one amino acid was synthesized (Fig. 1e) . The results from the Pepscan experiments have shown that 882 GFLCPEFPGSFRKKC 896 presents a profound reaction to the 3D8 mAb in contrast with the others (Fig. 1e) To define amino acids crucial to the epitope, the sequence 882 GFLCPEFPGSFRKKC 896 was further subjected to the alanine-scanning method by successively replacing each amino acid in the 15-mer peptide with alanine (synthesized by the Chu Tai Technology Co. Ltd). The procedure of alanine-scanning was similar to the iELISA described previously. Setting the binding rate between wild-type peptide and the 3D8 mAb as 100 %, replacing C by alanine resulted in an approximately 80 % binding rate. It implies that these amino acids were crucial to the binding efficiency. Additionally, the results were further strengthened by dot blot (Fig. 2a) and ECL-ELISA (Fig. 2b) (Fig. 2) . The and ECL-ELISA (b) were carried out to test the reactivity of these peptides to the 3D8 mAb. The amino acid residues which are substituted by alanines are underlined. 885 (Fig. 1c) to form a cyclic peptide as a similar report before (Gnann et al., 1987) . Previous studies have suggested that similar structures can enhance the binding efficiency between polypeptides and mAb (Koivunen et al., 1993 (Koivunen et al., , 1994 . This may explain why the no. 221 peptide 881 KGFLCPEFPG-SFRKK 895 initiated a weaker response to the 3D8 mAb (Fig. 1e) , which include the C-C circular structures, have lower responses to the 3D8 mAb ( Fig. 1c  and (Fig. 2) .
As we know, HFRS caused by HTNV infection is an epidemic disease with a high mortality rate, which is a major public health problem in many countries around the world. In addition to endangering the inhabitants in the endemic areas, HTNV is also a threat to tourists travelling in the affected areas in epidemic seasons as well as being a potential bioterrorism agent (Bui-Mansfield & Cressler, 2011; McCaughey & Hart, 2000) . Five phases were observed in the typical clinical courses of HFRS: febrile, hypotension, oliguria, polyuria and convalescence (Peters et al., 1999) . Generally, death occurs in the hypotension and oliguria phases (Xu et al., 2002) . At present, the primary treatment for HFRS is critical care management, including haemodialysis. These supportive measures may reduce the mortality rate (Peters et al., 1999) .
To date, there are no antivirals, vaccines or immunotherapeutics approved by the US Food and Drug Administration (FDA) for any of the haemorrhagic fever virus diseases, including HFRS and nephropathia epidemica. In China, although the inactivated vaccine against HFRS has been warranted, its efficacy still needs further evaluation. Ribavirin has both in vitro and in vivo antiviral activities to treat HFRS (Huggins et al., 1991) and hantavirus pulmonary syndrome (HPS) (Safronetz et al., 2011) . The efficacy of ribavirin as a treatment for hantavirus disease may depend on the phase of infection and the severity of disease at the time of the first administration of the drug (Rusnak et al., 2009) . Analyses of blood collected from HFRS patients show that patients remain viraemic during the acute phase of disease (Antoniades et al., 1987) . These results suggest that the administration of human neutralizing antibodies during this phase might prove effective for the treatment and/or prophylaxis of hantavirus infections. However, there have been no published reports on controlled clinical trials of immunotherapy for HFRS or HPS. To the best of our knowledge, the humanized mAb Synagis (palivizumab) is the only mAbs against a viral disease approved for clinical use by the US FDA, which has been widely used for the prevention of respiratory syncytial virus infections (Zhu et al., 2006) . A new candidate drug containing 3D8 and 3G1 neutralizing mAbs has completed all the clinical trials and the 'Application for the New Drug Certification' is in progress Xu, 2011) . Its curative efficacy is better than the conventional treatment (Xu, 2011 So far little research has been done on the mechanisms of neutralizing mAbs against viral infections. Some neutralizing mAbs directed against the receptor-binding domain (RBD) can block the interaction between RBD and the receptors for the virus. The epitopes binding to these neutralizing mAbs might be mimicking crucial motifs of RBD (Lü et al., 2009) . However, whether the RBD overlaps the epitopes of the 3D8 mAb needs further investigations.
Previous studies have indicated that HTNV antigenic sites defined by neutralizing mAbs are composed of discontinuous epitopes over both Gn and Gc proteins (Kikuchi et al., 1998) and most of them have been proposed to be conformational, as reflected by a high cysteine content of both proteins and the poor reactivity of the HFRS patients' sera with denatured GP . The peptides we synthesized have not been endowed with natural abilities, such as glycosylation and phosphorylation, which are the general characteristics of epitopes (Dowling et al., 2007) . Therefore, in the present study, the conformational structures of the epitopes remain unknown. One limitation of the present study is that the Pepscan technique can only be used to screen out simple linear epitopes; therefore, more sophisticated techniques are needed to identify other epitopes, discontinuous and conformational, of the 3D8 mAb and these epitopes on Gn as well.
As shown by Liang et al. (2003) , in the present study the 3D8 mAb is HTNV-specific. It cross-reacts with various HTNV strains, including 76-118, Chen and 84FLi, but fails to protect Vero E6 cells from infection of other HFRScausing hantaviruses (Table S1 , available in JGV Online). However, Koch et al. (2003) reported that the neutralizing antibodies they prepared bind to two epitopes 916 KVMATIDSF 924 and 954 LVTKDIDFD 963 . All of the neutralizing mAbs have the ability to cross-react with HTNV, Seoul virus (SEOV), Dobrava virus (DOBV) and Puumala virus (PUUV) . The discrepancy remains to be elucidated. The structural complexity of hantavirus envelope proteins should be considered. (Table 1) , the others are varying, some of which also contribute to the affinity of the 3D8 mAb binding. In addition, different sugars on the amino acids may also contribute to the conformation of the antibody-binding domain . We have learnt that there is also a conserved N-linked glycosylation site Asn-X-Ser nearby the epitope 882 GFLCPEFPGSF-RKKC 896 (30 aa downstream of the epitope).
In summary, the identification of a novel B-cell epitope of GPs recognized by the 3D8 mAb will help us to elucidate the mechanisms of the neutralization activity of the 3D8 mAb and to provide implications for hantavirus vaccinology. 
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*The amino acid sequences are numbered to represent the positions of each peptide. The core amino acid sequences of HTNV-Gc defined as the epitope for the 3D8 mAb and the identical sequences found in deduced amino acid sequences of SEOV-, DOBV-and PUUV-Gc are underlined.
